Keywords
How to Cite
Abstract
In this analysis, several therapeutic strategies for the treatment of Irritable Bowel Syndrome (IBS) are examined, with a focus on microbiota modulation and the use of specific medications. Initially, we highlight the effectiveness of recently developed pharmacological interventions, emphasizing their ability to control IBS symptoms and improve patients' quality of life. These emerging therapies not only aim to alleviate symptoms but also seek to address the underlying causes of the condition, taking into account the complex interaction between intestinal microbiota and environmental factors.
In addition to pharmacological interventions, innovative approaches such as modulation of intestinal microbiota are being explored to restore the balance of affected gut flora in IBS. These strategies include the use of probiotics, prebiotics, and symbiotics, which have been shown to promote gut health and reduce IBS symptoms in some patients. Ongoing research in this field is crucial for identifying the most effective microbial strains and better understanding how they can benefit individuals with IBS.
Furthermore, it is important to highlight the role of specific medications in the treatment of IBS, including antispasmodic agents, intestinal motility modulators, and visceral pain regulators. These medications aim to alleviate gastrointestinal symptoms such as abdominal pain, bloating, and changes in bowel movements, providing relief to patients affected by IBS.
In summary, the approach to treating Irritable Bowel Syndrome is increasingly focused on microbiota modulation and the use of specific medications. The integration of these therapeutic strategies can offer a more comprehensive and personalized approach to IBS management, significantly improving patients' quality of life. However, further research is needed to fully understand the underlying mechanisms and optimize the use of these therapeutic interventions in clinical practice.
References
Chang, L. et al. (2022). AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology, 163, 118–136.
Gargaria, G. et al. (2024). Collinsella aerofaciens as a predictive marker of response to probiotic treatment in non-constipated irritable bowel syndrome. Vol. 16, No. 1, 2298246.
Goodoory, V. C. et al. (2024). Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 22, 243–251.
Herekar, A. et al. (2023). Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management. Clinical and Experimental Gastroenterology, 16, 79–85.
Jamshidi, P. et al. (2023). Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Molecular Sciences, 24, 14562.
Khan, Z. et al. (2023). Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus, 15(9), e44807.
Menon, J. et al. (2023). Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial. Journal of Pediatric Gastroenterology and Nutrition (JPGN), 76(1).
Thomas, A., Thomas, A., & Butler-Sanchez, M. (2022). Dietary Modification for the Restoration of Gut Microbiome and Management of Symptoms in Irritable Bowel Syndrome. American Journal of Lifestyle Medicine, 16(5).
Tremblay, A., Xu, X., Colee, J., Tompkins, T. A., & Binda, S. (2023). Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis. Gastroenterology Insights, 14, 491–514.
Ustaoğlu, T., Acar Tek, N., & Yıldırım, A. E. (2024). Evaluation of the effects of the FODMAP diet and probiotics on irritable bowel syndrome (IBS) symptoms, quality of life and depression in women with IBS. Journal of Human Nutrition and Dietetics, 37, 5–17.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Larissa Fernanda Silva Bueno , José Henrique Soares Aragão, Ana Beatriz Tobias da Silva , Brenda Dias do Nascimento, Danilo Jahel Meireles
